| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10005436 | HBV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS10019441 | HBV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS10048786 | HBV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS30079989 | HIV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS30077211 | HIV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS30072378 | HIV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS20015392 | HPV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS20067885 | HPV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS20015235 | HPV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
| TVIS20015236 | HPV | ENSG00000186350.12 | protein_coding | RXRA | No | No | 6256 | P19793 Q6P3U7 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | RXRA |
|---|---|
| DrugBank ID | DB00307 |
| Drug Name | Bexarotene |
| Target ID | BE0000412 |
| UniProt ID | P19793 |
| Regulation Type | agonist |
| PubMed IDs | 11702369; 18765556; 17483357; 17008586; 15897247; 16495926; 14700480; 15632250; 15056048 |
| Citations | Lowe MN, Plosker GL: Bexarotene. Am J Clin Dermatol. 2000 Jul-Aug;1(4):245-50; discussion 251-2.@@Tsai DE, Luger SM, Andreadis C, Vogl DT, Kemner A, Potuzak M, Goradia A, Loren AW, Perl AE, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Thompson JE, Swider C, Bagg A, Mato AR, Carroll M: A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res. 2008 Sep 1;14(17):5619-25. doi: 10.1158/1078-0432.CCR-07-5185.@@Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW: Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 2007 May 1;67(9):4425-33.@@Lalloyer F, Fievet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A: The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7. Epub 2006 Sep 28.@@Yen WC, Lamph WW: The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther. 2005 May;4(5):824-34.@@Yen WC, Prudente RY, Corpuz MR, Negro-Vilar A, Lamph WW: A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours. Br J Cancer. 2006 Mar 13;94(5):654-60.@@Rizvi N, Hawkins MJ, Eisenberg PD, Yocum RC, Reich SD: Placebo-controlled trial of bexarotene, a retinoid x receptor agonist, as maintenance therapy for patients treated with chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2001 Feb;2(3):210-5.@@Rigas JR, Dragnev KH: Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist. 2005 Jan;10(1):22-33.@@Farol LT, Hymes KB: Bexarotene: a clinical review. Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. |
| Groups | Approved; Investigational |
| Direct Classification | Retinoids |
| SMILES | CC1=CC2=C(C=C1C(=C)C1=CC=C(C=C1)C(O)=O)C(C)(C)CCC2(C)C |
| Pathways | |
| PharmGKB | PA164752250 |
| ChEMBL | CHEMBL1023 |
